STAT's on-the-ground ESMO 2026 newsletter reports that the conference's most anticipated readout — Moderna and Merck's melanoma cancer vaccine (intismeran) — was upended by an embargo violation on the eve of the meeting, with companion coverage confirming the therapy met key endpoints and highlighting an 82% response rate for Tango's pancreatic cancer combo.
STAT's Readout newsletter (paywalled) covers Tango Therapeutics reporting an 82% tumor response rate for its vopimetostat combination (built on Revolution Medicines' pancreatic cancer franchise), Star Therapeutics' fundraise, and investors selling off Moderna stock despite its cancer vaccine meeting trial endpoints.
STAT publishes a caregiver's firsthand account of one family's journey through the clinical trial for daraxonrasib (Rasonque), the newly FDA-approved pancreatic cancer drug — humanizing color, not decision-grade intelligence.
Tango Therapeutics' vopimetostat combined with Revolution Medicines' Rasonque delivered an 82% tumor response rate in advanced pancreatic cancer, with 88% of patients alive and progression-free at nine months — chemo-free data presented at ESMO 2026 that validates the targeted-combination thesis in one of oncology's toughest indications.
Subscribe for real-time topic updates and unlimited access to our intelligence platform.